Godavari Biorefineries Limited — Q4 FY25 earnings call

Call held 26 May 2025

Management summary

Godavari Biorefineries reported a strong Q4 FY25, with revenue of INR 580 crores and EBITDA of INR 122 crores, driven by debottlenecking in bio-based chemicals and strong ethanol segment performance. FY25 revenue grew 11% to INR 1,870 crores. The company is strategically shifting towards bio-based specialty chemicals and green energy, targeting a 3x increase in EBITDA by FY29, despite ongoing margin pressures in the sugar and ethanol segments.

Highlights

  • Q4 FY25 Revenue from operations of INR 580 crores.

  • FY25 Revenue of INR 1,870 crores, up 11% YoY.

  • Q4 FY25 EBITDA of INR 122 crores, with a robust margin of 21%, an 80 bps increase YoY.

  • Biobased chemicals EBITDA grew more than 2x in FY25, underscoring strategic focus.

  • Highest ever cane crushing volumes at Sameerwadi facility: 24.6 lakh tons in sugar season 2024-25.

Concerns

  • FY25 PAT (excluding one-time deferred tax) was INR 1.1 crores, with a PAT margin of 0.1%.

  • Industry-wide margin pressure in sugar and ethanol due to higher cane prices and unchanged ethanol procurement prices since November 2022.

  • Cellulose and 2G ethanol projects are still in research and business development, not near commercialization.

Key financials

3 periods

Q4 FY25

  • Revenue
    ₹580 Cr
  • EBITDA
    ₹122 Cr
  • EBITDA Margin
    21%
    YoY +4%

FY25

  • Revenue
    ₹1,870 Cr
    YoY +11%
  • EBITDA
    ₹120 Cr

FY25, ex-deferred tax

  • PAT
    ₹1.1 Cr

What they filed

Q1 FY27: revenue up 3.6%, net profit down 23.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue316 445 576 523 423 +34%457 +3%562 −2%542 +4%
EBITDA-34 37 110 5 -9 +74%43 +16%86 −22%-2 −140%
Net profit-76 6 70 -17 -43 +43%8 +33%52 −26%-21 −24%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Chemical Segment
    ₹540 Cr Revenue (FY25)₹38 Cr EBITDA (FY25)

Capital allocation

medium confidence
  • Capex ₹130 Cr
    • Grain-based ethanol facility (net of GST) ₹130 Cr
    • De-bottlenecking of bio-based chemicals
    For FY '26, we are investing currently in the grain-based ethanol facility for which our capital expenditure was estimated to be INR130 crores. That is net of GST. And we are also going to invest in de-bottlenecking of bio-based chemicals.
  • Debt Debt disclosed
    We have strengthened our financial position by reducing debt, which has lowered our interest burden and created significant headroom for future expansion and strategic investments.

Guidance & targets

Profitability

  • EBITDA Profitability · by FY29 · High confidence 3x of FY25 EBITDA (INR 360 crores)
    With these initiatives and subject to climate policy and unforeseen risks, we are targeting an increase in EBITDA by about 3x of FY25 numbers by FY29.

    — Samir Somaiya

Capacity

  • Grain/Maize Distillery Commissioning Capacity · Q4 FY26 · High confidence Operational
    Our 200-kiloliter-per-day fungible grain/maize distillery is expected to be commissioned in Q4 financial year 26.

    — Samir Somaiya

  • Biobutanol and Higher Alcohols Capacity (Phase 1) Capacity · Ongoing implementation in phases · Medium confidence 15,000 tons
    We have done this license for 30,000 tons and we were implementing it in phases, which is first phase to be 15,000 tons.

    — Samir Somaiya

Research & Development

  • Cancer Molecule Safety Trials Completion Research & Development · Q2 FY26 · High confidence Complete
    And this safety trial is expected to be complete in Q2 FY '26.

    — Samir Somaiya

  • Cancer Molecule Preliminary Efficacy Trials Duration Research & Development · After Q2 FY26 · Medium confidence 2+ years
    Our current estimate of preliminary efficacy subject to a successful completion of the safety trials would be in the range of two years, two plus.

    — Samir Somaiya

What to watch in Q1 FY26

Clarity on Biobutanol and Higher Alcohols Project Cost

Next quarterly meeting
Current Working on detailed engineering package for the licensed molecule.
Target Better idea of the cost.

Why it matters

This project is a key part of the strategic shift to specialty chemicals, and cost clarity is crucial for financial planning and investor confidence.

We do think that we will have a much better idea of the cost of this molecule by our next quarterly meeting.

Risks & concerns

  • Margin pressure in sugar and ethanol segments

    high

    Due to increased cane prices (FRP) and unchanged ethanol procurement prices since November 2022, partially mitigated by sugar export quota.

    Management acknowledged

  • Macroeconomic pressures and challenging external environment

    medium

    Across core verticals: sugar, ethanol, bio-based chemicals.

    Management acknowledged

  • Climate policy and unforeseen risks

    low

    General risk mentioned in context of future EBITDA targets.

    Management acknowledged

Q&A highlights

6 direct, 1 evasive
Strategic shift and sustainable EBITDA/PAT margins Direct
we talked about EBITDA, that we would look at 3x of FY25 numbers, and that will be accompanied by directional change, strategic shifts in two places. One is in the green energy transformation in India... The other strategic shift is to add bio-based chemicals, which are in the Spec chemical space...

Provides the core long-term financial target (3x EBITDA by FY29) and the two main strategic pillars to achieve it.

Asked by Vivek Gupta

Strong Q4 EBITDA in the chemical segment Direct
The whole strategy of financial transformation was to release cash flows by having and that cash flows was to be used in debottlenecking bio-based spec chemicals for which we have demand. We are seeing that demand and we are working on debottlenecking chemical capacity to meet that demand.

Explains the immediate driver for strong chemical segment performance (debottlenecking) and links it to the broader financial transformation strategy.

Asked by Dhavan Shah

Breakdown of 3x EBITDA target between sugar/ethanol and chemicals Evasive
I think we would not like to specify this right now. Our strategic shift is across the entire green transformation in what we call the bio-refining space.

Management declined to provide a segment-wise split for the ambitious FY29 EBITDA target, indicating either lack of detailed internal targets or unwillingness to disclose.

Asked by Dhavan Shah

Impact of uniform sugar export quota of 1 million tons Direct
I definitely think of this export of sugar as a positive step. The reason is that the cane prices were increased against last year. And there was no corresponding increase announced by the government for the ethanol price... So what the announcement of the export quota... improved domestic sugar prices from end February or March onwards and will certainly relieve the margin pressure on sugar...

Provides management's view on a key regulatory development impacting the sugar business, highlighting its positive effect on sugar prices and margin relief.

Asked by Raj Patel

Cancer molecule research as a non-core business, timeline, and future cash flow Partial
Our aim would be to out-license this molecule and look for opportunities there... Our current estimate of preliminary efficacy subject to a successful completion of the safety trials would be in the range of two years, two plus.

Clarifies the company's strategy for this non-core asset (out-licensing) and provides a timeline for further development before that can happen, but avoids quantifying future spend.

Asked by Kranthi Bathini

Outlook on distillery margins Direct
margins in sugar and ethanol came under pressure in light of the higher cane prices without a corresponding increase in either the MSP of sugar or the ethanol being fed to the blending program... The export quota announced by the government in late February helped the sugar prices improve... As far as ethanol is concerned, we will await the government announcements for what the pricing will be for the ethanol year from 1st November onwards.

Explains the margin pressure faced by the ethanol segment and highlights the dependency on future government pricing announcements for the next ethanol year.

Asked by Himanshu Dugar

Alignment of cancer molecule initiative with core strategic direction Direct
Our strategic focus remains on the bio transformations of agriculture feedstock. But Godavari always looks at blue sky transformations... An idea had also come that based on our research scholars, whether we could do work on also a drug discovery molecule just to establish possibilities and potential.

Management explains the rationale behind pursuing a non-core, high-risk/high-reward project as part of broader 'blue sky thinking' and establishing potential, rather than a direct alignment with current core business.

Asked by Mamta Agarwal

Update on cellulose/derivatives and 2G ethanol project Direct
As far as cellulose and cellulose derivatives and 2G is concerned, these are currently in research and business development.

Clarifies that these projects are still in early R&D, not near commercialization, contrasting with other projects like grain-based ethanol.

Asked by Vivek Gupta

2 min read 6 chapters

Detailed narrative

Q4 & FY25 Financial Performance Overview

Godavari Biorefineries reported strong financial results for Q4 FY25, with revenue from operations reaching INR 580 crores. For the full fiscal year 2025, revenue increased by 11% to INR 1,870 crores. Q4 FY25 EBITDA stood at INR 122 crores, achieving a robust margin of 21%, an 80 basis point improvement from 20.2% in Q4 FY24. However, FY25 PAT, excluding one-time deferred tax, was modest at INR 1.1 crores, resulting in a 0.1% PAT margin.

Strategic Pivot to Bio-based Chemicals and Green Energy

The company is undergoing a strategic transformation towards bio-based specialty chemicals and renewable energy, aiming for an increase in EBITDA by about 3x of FY25 numbers by FY29. This involves diversifying feedstock capabilities and reducing reliance on ethyl acetate. Godavari Biorefineries is actively co-creating solutions with global companies transitioning to lower carbon footprints, leveraging its expertise in renewable sources.

Ethanol Segment Growth and Future Capacity

The ethanol segment delivered exceptional performance in Q4 FY25, with revenue growth of 37%, supported by the government's decision to restore the ethanol blending program from sugarcane juice/syrup. To further expand its presence in green energy, the company is investing in a 200-kiloliter-per-day fungible grain/maize distillery, expected to be commissioned in Q4 FY26. This will enhance ethanol capacity and multi-feedstock flexibility, positioning the company for sustained growth.

Sugar Industry Dynamics and Government Support

India's sugar output declined significantly in FY25 due to lower cane yields, while the Fair and Remunerative Price (FRP) for cane increased. This created margin pressure for the industry as ethanol procurement prices remained unchanged since November 2022. However, the government's recent decision to allow a uniform export quota of 1 million tons for sugar helped stabilize domestic supply and support sugar prices, providing some relief to industry margins.

Research & Development: Cancer Molecule Initiative

Godavari Biorefineries has been engaged in 'blue sky thinking' research, including a drug discovery molecule for triple-negative breast cancer. The company has spent approximately INR 25 crores over the last 10 years on this project. Safety trials for this molecule are expected to be complete in Q2 FY26, with preliminary efficacy trials estimated to take two years or more thereafter. The strategic aim is to out-license this molecule to pharmaceutical companies after successful trials, as it is not a core business for Godavari.

Capital Expenditure and Future Growth Drivers

For FY26, the company plans a capital expenditure of INR 130 crores (net of GST) for the grain-based ethanol facility. Additionally, investments are being made in de-bottlenecking initiatives to optimize existing production capacities in bio-based chemicals. The company has also licensed technology for biobutanol and higher alcohols, with a planned capacity of 30,000 tons, with the first phase targeting 15,000 tons, which will significantly boost its sustainable chemistry portfolio.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Fast Moving Consumer Goods earnings calls